Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multi-Center, 1-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 to <6 Years of Age With Rare Genetic Causes of Obesity

NCT04966741 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04966741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multi-Center, 1-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 to <6 Years of Age With Rare Genetic Causes of Obesity
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2022
Completion date
November 8, 2024
Enrollment
12 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bardet-biedl syndrome, lepr deficiency obesity, pcsk1 deficiency obesity, pomc deficiency obesity